Preferred Label : CD137/PSMA/HSA Trispecific-targeting Agent CB 307;
NCIt synonyms : CD137 x PSMA Humabody CB307; Tri-specific Humabody CB307; Trispecific Humabody T-cell Enhancer CB307;
NCIt definition : A trispecific T-cell enabler targeting the human tumor-associated antigen (TAA) prostate-specific
membrane antigen (PSMA; FOLH1), the co-stimulatory receptor 4-1BB (CD137; tumor necrosis
factor receptor superfamily member 9; TNFRSF9) and human serum albumin (HSA), with
potential immunostimulating and antineoplastic activities. Upon administration, CD137/PSMA/HSA
trispecific-targeting agent CB307 simultaneously targets and binds to 4-1BB, which
is expressed on a variety of leukocyte subsets including activated T-lymphocytes,
and PSMA expressed on tumor cells. The simultaneous binding to PSMA enables clustering
of 4-1BB and thereby allows for conditional stimulation of 4-1BB signaling within
the tumor microenvironment (TME) only upon binding to PSMA on tumor cells. 4-1BB activation
results in T-cell stimulation and enhances T-lymphocyte-mediated anti-tumor immune
response against the PSMA-expressing tumor cells. PSMA is overexpressed on the surface
of metastatic and hormone-refractory prostate tumor cells. 4-1BB, a surface glycoprotein
of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor
that plays a key role in T-cell proliferation, survival and cytolytic activity. The
albumin-binding domain targets and binds to HSA thereby extending the serum half-life
of CB307. The conditional activation of 4-1BB signaling prevents systemic T-cell activation
and lowers systemic toxicity.;
Molecule name : CB 307; CB-307;
NCI Metathesaurus CUI : CL1662929;
Origin ID : C180592;
UMLS CUI : C5556484;
Semantic type(s)
- concept_is_in_subset
- has_target
